LTL-351A datasheet

Origin	Primary human ovarian cancer	**Histopathology**	High grade serous carcinoma
Year of establishment	2009	**Doubling time**	15 days (sub-renal)
Local invasion	No	**Metastasis**	Yes (micrometastasis)
Drug sensitivity	Not determined		

The LTL-351A was developed from a patient's primary ovarian cancer (high grade serous carcinoma). Histopathologically, it closely resembles the patient's cancer (Figs 1, 2). When grafted under the renal capsules of SCID mice, the LTL-351A shows no local invasion into adjacent host kidney parenchyma. Micrometastases to pulmonary parenchyma were observed in some hosts.



Fig 1. H&E stained LTL-351A tissue sections

The LTL-351A shows histopathological characteristics similar to those of the patient's cancer tissue before grafting (Fig 2). (x200)



Fig. 2. Patient's cancer tissue before grafting.

Major histopathological characteristics:

- High grade serous carcinoma
- Glandular structure with slit-like lumena
- Infiltration by large amount of of inflammatory cells
- Presence of large necrotic areas (arrows)

(x200)

Genetic and epigenetic characteristics

Tissue microarrays containing LTL-351A tissue are available for screening potential molecular targets.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis) and angiogenesis.

2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.

3. Study of mechanisms underlying tumor growth and progression.

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013